Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$11.48 - $17.69 $384,488 - $592,473
-33,492 Closed
0 $0
Q3 2021

Nov 17, 2021

BUY
$14.57 - $17.72 $487,978 - $593,478
33,492 New
33,492 $519,000

Others Institutions Holding ALGS

About Aligos Therapeutics, Inc.


  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $751M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.